Skip to content
Homepage
Author:
Terns Pharmaceuticals, Inc.
Posted Date:
May 26, 2026
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc.
May 26, 2026
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc.
May 23, 2026
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns Pharmaceuticals, Inc.
May 22, 2026
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Terns Pharmaceuticals, Inc.
April 29, 2026
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc.
February 2, 2026
